Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Receivables (2022 - 2025)

Amylyx Pharmaceuticals (AMLX) has 4 years of Change in Receivables data on record, last reported at -$44000.0 in Q4 2025.

  • For Q4 2025, Change in Receivables rose 96.57% year-over-year to -$44000.0; the TTM value through Dec 2025 reached -$359000.0, up 99.09%, while the annual FY2025 figure was -$359000.0, 99.09% up from the prior year.
  • Change in Receivables reached -$44000.0 in Q4 2025 per AMLX's latest filing, down from $30000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $15.9 million in Q2 2023 and bottomed at -$19.7 million in Q1 2024.
  • Average Change in Receivables over 4 years is -$3692.3, with a median of -$147000.0 recorded in 2025.
  • Peak YoY movement for Change in Receivables: tumbled 975.86% in 2024, then skyrocketed 101.27% in 2025.
  • A 4-year view of Change in Receivables shows it stood at $15.2 million in 2022, then decreased by 29.48% to $10.7 million in 2023, then crashed by 111.99% to -$1.3 million in 2024, then surged by 96.57% to -$44000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$44000.0 in Q4 2025, $30000.0 in Q3 2025, and -$198000.0 in Q2 2025.